Teva Pharmaceutical Industries Limited Stock TEL AVIV STOCK EXCHANGE
Stocks
TEVA
IL0006290147
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9,642.00 ILa | -0.96% |
|
-2.96% | -4.44% |
| 07-09 | Teva Pharmaceuticals Obtains Rights to Commercialize Polpharma's Biosimilar Candidate to Ocrevus | MT |
| 07-09 | Teva, Samsung Bioepis Partner to Commercialize Eylea Biosimilar Opuviz in Canada | MT |
| Market Cap | 37.3B 11,386B 32.69B 30.23B 27.79B 52.52B 3,597B 53.33B 361B 141B 1,758B 140B 137B 6,061B | P/E 2026 * |
38.3x | P/E 2027 * | 16.9x |
|---|---|---|---|---|---|
| Enterprise Value | 48.48B 14,800B 42.49B 39.29B 36.12B 68.27B 4,675B 69.32B 469B 184B 2,286B 182B 178B 7,878B | EV / Sales 2026 * |
2.91x | EV / Sales 2027 * | 2.65x |
| Free-Float |
88.61% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Teva Pharmaceutical Industries Limited
| 1 day | -0.96% | ||
| 1 week | -2.96% | ||
| Current month | -1.98% | ||
| 1 month | +2.23% | ||
| 3 months | +2.90% | ||
| 6 months | -3.38% | ||
| Current year | -4.44% |
| 1 week | 9,460 | 9,930 | |
| 1 month | 9,277 | 10,730 | |
| Current year | 8,860 | 11,350 | |
| 1 year | 5,305 | 11,350 | |
| 3 years | 3,002 | 11,350 | |
| 5 years | 2,383 | 11,350 | |
| 10 years | 2,175 | 21,320 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 57 | 01/01/2023 |
Eli Kalif
DFI | Director of Finance/CFO | 53 | 22/12/2019 |
Matthew Shields
COO | Chief Operating Officer | 52 | 03/06/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Amir Elstein
BRD | Director/Board Member | 69 | 01/01/2009 |
Sol Barer
CHM | Chairman | 78 | 06/02/2017 |
Rosemary Crane
BRD | Director/Board Member | 65 | 01/09/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.96% | -2.96% | - | - | 37.3B | ||
| -2.73% | -3.51% | +48.62% | +152.87% | 1,051B | ||
| -1.67% | -3.18% | +52.00% | +56.75% | 609B | ||
| -0.44% | +2.14% | +33.88% | +84.04% | 450B | ||
| -0.75% | -1.46% | +28.32% | +22.33% | 330B | ||
| -1.52% | -0.95% | +33.38% | +38.39% | 284B | ||
| -1.70% | -3.54% | +20.26% | +17.88% | 263B | ||
| -0.58% | +1.78% | -20.89% | -38.37% | 223B | ||
| -0.58% | +0.21% | +23.55% | +56.94% | 198B | ||
| -0.80% | +2.60% | +23.09% | +68.71% | 167B | ||
| Average | -0.60% | +0.54% | +26.91% | +51.06% | 397.23B | |
| Weighted average by Cap. | -0.11% | +0.02% | +35.25% | +75.58% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.64B 5,081B 14.59B 13.49B 12.4B 23.44B 1,605B 23.8B 161B 63.12B 785B 62.49B 61.13B 2,705B | 17.24B 5,263B 15.11B 13.97B 12.84B 24.28B 1,663B 24.65B 167B 65.38B 813B 64.73B 63.32B 2,801B |
| Net income | 1.31B 400B 1.15B 1.06B 975M 1.84B 126B 1.87B 12.66B 4.96B 61.72B 4.92B 4.81B 213B | 2.46B 752B 2.16B 2B 1.84B 3.47B 238B 3.52B 23.83B 9.34B 116B 9.25B 9.05B 400B |
| Net Debt | 11.18B 3,414B 9.8B 9.06B 8.33B 15.75B 1,078B 15.99B 108B 42.41B 527B 41.99B 41.08B 1,817B | 8.44B 2,575B 7.39B 6.84B 6.29B 11.88B 813B 12.06B 81.6B 31.99B 398B 31.67B 30.98B 1,371B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/07/26 | ILA 9,642.00 | -0.96% | 759,073 |
| 17/07/26 | ILA 9,735.00 | -0.41% | 485,235 |
| 16/07/26 | ILA 9,775.00 | +2.57% | 1,284,861 |
| 15/07/26 | ILA 9,530.00 | -0.16% | 599,684 |
| 14/07/26 | ILA 9,545.00 | -3.00% | 991,824 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- TEVA Stock
- TEVA Stock
Select your edition
All financial news and data tailored to specific country editions


















